Naropeine
Phase 3Small molecule
Naropeine is one of 41 small molecule programs targeting Hysterectomy. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
49 competitors in Hysterectomy
#DrugCompanyPhaseTrials
1Toradol
RocheApproved
Golytely
BayerApproved
Medrol
PfizerApproved
Atarax
PfizerApproved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Marcaine
IInnocoll
Approved
Oxycontin
PProtega
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Naropeine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- NNantes University Hospital